Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of FULC traded up $0.09 during midday trading on Friday, hitting $3.77. The company had a trading volume of 1,364,507 shares, compared to its average volume of 1,300,025. The company’s 50-day simple moving average is $3.73 and its 200-day simple moving average is $5.55. The firm has a market capitalization of $287.95 million, a P/E ratio of -3.62 and a beta of 2.82. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Equities analysts predict that Fulcrum Therapeutics will post -0.60 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $35,000. ProShare Advisors LLC acquired a new stake in Fulcrum Therapeutics in the third quarter worth about $41,000. China Universal Asset Management Co. Ltd. grew its position in Fulcrum Therapeutics by 31.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,921 shares of the company’s stock valued at $52,000 after buying an additional 3,316 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Fulcrum Therapeutics during the second quarter valued at approximately $61,000. Finally, Nisa Investment Advisors LLC raised its stake in shares of Fulcrum Therapeutics by 538.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 20,177 shares of the company’s stock worth $75,000 after buying an additional 17,016 shares in the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.